Background: One of the contributing factors to ocular surface health is a stable precorneal tear film. Considering the increasing interest in rabbits as pets and the limited literature available on domestic rabbit tearing, the aim of this study was to establish normative data for examination of the tear film in domestic rabbits.

Results: The study included 75 client-owned domestic Holland Lop rabbits (150 eyes). The following examinations were performed in each eye: Schirmer tear test-1, tear osmometry, interferometry, tear meniscus height measurement and meibography (quantifying meibomian gland loss as a percentage). The resulting median (95% central range) values were 10.0 (5.0-17.3) mm/min for the Schirmer tear test-1, 345.0 (280.5-376.1) mOsm/L for tear osmolarity, grade 2 (1-4) of interferometry, 0.28 (0.20-0.47) mm for tear meniscus height and 0.0 (0.0-67.6) % meibomian gland loss. A significant association was found between tear osmolarity and age, with an estimated decrease of - 4.0 mOsm/L with each additional year of age (p < 0.001). The distributions of interferometry grades were significantly different between males and females (p < 0.001), with grade 1 and grade 2 being the most frequent in females and males, respectively. A weak negative correlation was also observed between interferometry grade and the percentage of meibomian gland loss (r = - 0.22, p = 0.006).

Conclusions: This is an original study that documents extensive tear film parameters in healthy Holland Lop rabbits. The results can be used as normative data for the examination of the tear film in this lagomorph breed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652783PMC
http://dx.doi.org/10.1186/s12917-022-03492-1DOI Listing

Publication Analysis

Top Keywords

tear film
12
tear
10
schirmer tear
8
tear test-1
8
tear meniscus
8
meniscus height
8
meibomian gland
8
gland loss
8
tear osmolarity
8
clinical parameters
4

Similar Publications

Background: Overexpression of tear matrix metalloproteinases-9 (MMP-9) on the ocular surface tissues has been reported to result in ocular surface damage. MMP-9 levels in tears have been listed as one of many tools for confirming dry eye disease (DED).

Objective: This investigation aimed to compare MMP-9 levels and ocular surface parameters in diabetic patients with and without DED.

View Article and Find Full Text PDF

An update on emerging pharmacological treatments for meibomian gland dysfunction.

Expert Opin Pharmacother

January 2025

Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.

Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.

View Article and Find Full Text PDF

Dry eye disease (DED) is a multifactorial condition with complex and incompletely understood molecular mechanisms. Advances in multi-omics technologies, including genomics, transcriptomics, proteomics, metabolomics, and microbiomics, have provided new insights into the pathophysiology of DED. Genomic analyses have identified key genetic variants linked to immune regulation and lacrimal gland function.

View Article and Find Full Text PDF

Clinical practice patterns in the management of dry eye disease: A TFOS international survey 2023-4.

Ocul Surf

December 2024

Centre for Ocular Research and Education (CORE), School of Optometry and Vision Science, University of Waterloo, Canada; Optometry and Vision Science Research Group, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom; Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, New Zealand.

Aims: To understand current clinical management of dry eye disease (DED), based on its perceived severity and subtype by practitioners across the world.

Methods: The content of the anonymous survey was chosen to reflect the DED management strategies reported by the Tear Film and Ocular Surface Society (TFOS) 2 Dry Eye Workshop (DEWS II). Questions were designed to ascertain practitioner treatment choice, depending on the subtype and severity of DED.

View Article and Find Full Text PDF

Hyaluronan-modified nanoceria for dry eye disease treatment.

J Colloid Interface Sci

December 2024

Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310009, China. Electronic address:

Dry eye disease (DED), a prevalent ocular disorder, affects nearly half the global population, bringing enormous health and economic burden. Currently, the predominant treatments for DED involve the administration of artificial tears, which is often hindered by continuous administration and constant reactive oxygen species (ROS) stimulus. Therefore, hyaluronan (HA)-modified cerium oxide (CeO) nanoparticles, HA-CeO, were developed to achieve simultaneous ROS scavenging and enhanced tear film stability.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!